Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives

A meeting that was organized by the Academy of Pharmaceutical Sciences Biopharmaceutics and Regulatory Sciences focus groups focused on the challenges of Developing Clinically Relevant Dissolution Specifications (CRDS) for Oral Drug Products. Industrial Scientists that were involved in product development shared their experiences with in vitro dissolution and in silico modeling approaches to establish clinically relevant dissolution specifications. The regulators shared their perspectives on the acceptability of these different strategies for the development of acceptable specifications. The meeting also reviewed several collaborative initiatives that were relevant to regulatory biopharmaceutics. Following the scientific presentations, a roundtable session provided an opportunity for delegates to discuss the information that was shared during the presentations, debate key questions, and propose strategies to make progress in this critical area of regulatory biopharmaceutics. It was evident from the presentations and subsequent discussions that progress continues to be made with approaches to establish robust CRDS. Further dialogue between industry and regulatory agencies greatly assisted future developments and key areas for focused discussions on CRDS were identified.

[1]  R. Guy,et al.  International Conference on Harmonisation , 2014 .

[2]  Andre Hermans,et al.  Dissolution Testing in Drug Product Development: Workshop Summary Report , 2019, The AAPS Journal.

[3]  Talia Flanagan,et al.  Approaches for Establishing Clinically Relevant Dissolution Specifications for Immediate Release Solid Oral Dosage Forms , 2017, The AAPS Journal.

[4]  M. Sanaka,et al.  Use of salivary acetaminophen concentration to assess gastric emptying rate of liquids , 2000, Journal of Gastroenterology.

[5]  Ping Zhao,et al.  Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status , 2017, CPT: pharmacometrics & systems pharmacology.

[6]  H. Parkman,et al.  Wireless Capsule Motility: Comparison of the SmartPill® GI Monitoring System with Scintigraphy for Measuring Whole Gut Transit , 2009, Digestive Diseases and Sciences.

[7]  Paul A. Dickinson,et al.  Clinical Relevance of Dissolution Testing in Quality by Design , 2008, The AAPS Journal.

[8]  Andreas M. Abend,et al.  Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization. , 2018, Journal of pharmaceutical sciences.

[9]  Filippos Kesisoglou,et al.  Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report , 2018, The AAPS Journal.

[10]  J. Tack,et al.  Exploring the link between gastric motility and intragastric drug distribution in man , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  P. Dickinson,et al.  Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products , 2017 .

[12]  Martin Bergstrand,et al.  In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status , 2017, Pharmaceutical Research.

[13]  F. Kesisoglou,et al.  Application of Absorption Modeling to Predict Bioequivalence Outcome of Two Batches of Etoricoxib Tablets , 2015, AAPS PharmSciTech.

[14]  Anette Müllertz,et al.  The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. , 2014, Journal of pharmaceutical sciences.

[15]  H. Mönnikes,et al.  Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Amitava Mitra,et al.  Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link—a Workshop Summary Report , 2019, The AAPS Journal.

[17]  Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action , 2017 .

[18]  Paul F. Reynolds,et al.  The Role of Modeling and Simulation , 2008 .

[19]  N. Patel,et al.  Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug. , 2017, Molecular pharmaceutics.

[20]  Anna Eidelman,et al.  Justification of Drug Product Dissolution Rate and Drug Substance Particle Size Specifications Based on Absorption PBPK Modeling for Lesinurad Immediate Release Tablets. , 2016, Molecular pharmaceutics.

[21]  Talia Flanagan,et al.  Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. , 2016, Journal of pharmaceutical sciences.

[22]  Filippos Kesisoglou,et al.  Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report , 2018, The AAPS Journal.

[23]  Sarfaraz K. Niazi Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.